Daiichi Sankyo begins patient dosing in phase 2 trial of mRNA vaccine, DS-5670 against Covid-19

Daiichi Sankyo Company, Limited announced that the first patient has been dosed in a phase 2 trial in Japan of DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (Covid-19). This phase 2 trial is being conducted in 80 unvaccinated healthy adults using a batch of DS-5,670 from the optimized manufacturing process to evaluate the safety and determine the recommended dose of DS-5670. If successful, a phase 3 trial of DS-5670 will be initiated within FY2021. Daiichi Sankyo also will continue discussions with the Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) to determine next steps for initiating development of a supplemental (booster) dose of DS-5670 by January 2022. As a Japanese pharmaceutical company with a specialty in developing vaccines, Daiichi Sankyo is striving to help restore safety and security in society through the early eradication of Covid-19, which it hopes to achieve by pursuing the development and commercialization of DS-5670 in Japan during 2022. DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by Daiichi Sankyo. It is anticipated to be safe and efficacious by targeting the receptor binding domain (RBD) of the new coronavirus. The clinical development of DS-5670 is being conducted through

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!